SK284639B6 - Použitie komplexných lipidov ako stabilizujúcich prísad do farmaceutických prípravkov zmesí zažívacích enzýmov - Google Patents

Použitie komplexných lipidov ako stabilizujúcich prísad do farmaceutických prípravkov zmesí zažívacích enzýmov Download PDF

Info

Publication number: SK284639B6
Authority: SK; Slovakia
Prior art keywords: complex lipids; pancreatin; mixtures; pharmaceutical preparations; lipase
Prior art date: 1996-08-28

Application number

SK1159-97A

Other languages

English (en)

Slovak (sk)

Other versions

SK115997A3 (en

Inventor

Manfred Galle

Original Assignee

Solvay Pharmaceuticals Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-28

Filing date

1997-08-22

Publication date

2005-08-04

1997-08-22 Application filed by Solvay Pharmaceuticals Gmbh filed Critical Solvay Pharmaceuticals Gmbh

1998-07-08 Publication of SK115997A3 publication Critical patent/SK115997A3/sk

2005-08-04 Publication of SK284639B6 publication Critical patent/SK284639B6/sk

Links

239000000203 mixture Substances 0.000 title claims abstract description 105
102000038379 digestive enzymes Human genes 0.000 title claims abstract description 63
108091007734 digestive enzymes Proteins 0.000 title claims abstract description 63
150000002632 lipids Chemical class 0.000 title claims abstract description 57
239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 27
239000000654 additive Substances 0.000 title claims description 14
230000000087 stabilizing effect Effects 0.000 title claims description 12
239000004367 Lipase Substances 0.000 claims abstract description 60
108090001060 Lipase Proteins 0.000 claims abstract description 57
102000004882 Lipase Human genes 0.000 claims abstract description 57
235000019421 lipase Nutrition 0.000 claims abstract description 57
230000002366 lipolytic effect Effects 0.000 claims abstract description 51
108091005804 Peptidases Proteins 0.000 claims abstract description 43
235000010445 lecithin Nutrition 0.000 claims abstract description 43
239000000787 lecithin Substances 0.000 claims abstract description 43
239000004365 Protease Substances 0.000 claims abstract description 42
239000007864 aqueous solution Substances 0.000 claims abstract description 26
102000035195 Peptidases Human genes 0.000 claims abstract description 20
230000007423 decrease Effects 0.000 claims abstract description 20
210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 9
229940055695 pancreatin Drugs 0.000 claims description 79
239000000243 solution Substances 0.000 claims description 71
108010019160 Pancreatin Proteins 0.000 claims description 63
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
238000002360 preparation method Methods 0.000 claims description 28
239000000523 sample Substances 0.000 claims description 24
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 23
150000003904 phospholipids Chemical class 0.000 claims description 23
-1 alkanoyl radical Chemical class 0.000 claims description 19
230000000694 effects Effects 0.000 claims description 17
229910052739 hydrogen Inorganic materials 0.000 claims description 16
239000001257 hydrogen Substances 0.000 claims description 16
125000004432 carbon atom Chemical group C* 0.000 claims description 13
239000007787 solid Substances 0.000 claims description 13
241000196324 Embryophyta Species 0.000 claims description 10
244000005700 microbiome Species 0.000 claims description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
238000000034 method Methods 0.000 claims description 9
229930186217 Glycolipid Natural products 0.000 claims description 7
150000002431 hydrogen Chemical class 0.000 claims description 7
150000003254 radicals Chemical class 0.000 claims description 7
230000006641 stabilisation Effects 0.000 claims description 7
238000011105 stabilization Methods 0.000 claims description 7
150000001768 cations Chemical class 0.000 claims description 6
238000004362 fungal culture Methods 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
239000002904 solvent Substances 0.000 claims description 5
244000068988 Glycine max Species 0.000 claims description 4
235000010469 Glycine max Nutrition 0.000 claims description 4
238000003304 gavage Methods 0.000 claims description 4
230000012010 growth Effects 0.000 claims description 4
125000001183 hydrocarbyl group Chemical group 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
244000105624 Arachis hypogaea Species 0.000 claims description 3
239000004215 Carbon black (E152) Substances 0.000 claims description 3
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
150000001721 carbon Chemical group 0.000 claims description 3
235000013601 eggs Nutrition 0.000 claims description 3
229930195733 hydrocarbon Natural products 0.000 claims description 3
239000004615 ingredient Substances 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
239000001301 oxygen Substances 0.000 claims description 3
235000020232 peanut Nutrition 0.000 claims description 3
150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
238000012545 processing Methods 0.000 claims description 3
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
235000003222 Helianthus annuus Nutrition 0.000 claims description 2
240000008042 Zea mays Species 0.000 claims description 2
235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
150000001723 carbon free-radicals Chemical class 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
238000011084 recovery Methods 0.000 claims description 2
230000001580 bacterial effect Effects 0.000 claims 2
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
241000208818 Helianthus Species 0.000 claims 1
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims 1
150000001450 anions Chemical class 0.000 claims 1
125000002160 cholyl group Chemical group [H]C([H])([C@]1(C([C@@]2([H])O[H])([H])[H])[H])[C@@](O[H])([H])C([H])([H])C([H])([H])[C@]1(C([H])([H])[H])[C@]1([H])[C@]2([H])[C@]2([H])C([H])([H])C([H])([H])[C@@]([C@](C([H])([H])[H])(C(C(C(=O)[*])([H])[H])([H])[H])[H])([H])[C@@]2(C([H])([H])[H])[C@](O[H])([H])C1([H])[H] 0.000 claims 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
235000009973 maize Nutrition 0.000 claims 1
125000002072 seryl group Chemical group 0.000 claims 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract description 33
229940067606 lecithin Drugs 0.000 abstract description 33
235000019626 lipase activity Nutrition 0.000 description 21
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
102000004190 Enzymes Human genes 0.000 description 19
108090000790 Enzymes Proteins 0.000 description 19
229940088598 enzyme Drugs 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
238000011534 incubation Methods 0.000 description 15
239000000126 substance Substances 0.000 description 15
239000000843 powder Substances 0.000 description 13
239000008347 soybean phospholipid Substances 0.000 description 11
239000012085 test solution Substances 0.000 description 11
239000011780 sodium chloride Substances 0.000 description 10
239000000725 suspension Substances 0.000 description 10
241000235527 Rhizopus Species 0.000 description 9
239000000839 emulsion Substances 0.000 description 9
210000000496 pancreas Anatomy 0.000 description 9
239000008194 pharmaceutical composition Substances 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
239000004006 olive oil Substances 0.000 description 8
235000008390 olive oil Nutrition 0.000 description 8
238000004448 titration Methods 0.000 description 7
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
230000002496 gastric effect Effects 0.000 description 5
230000000813 microbial effect Effects 0.000 description 5
230000002797 proteolythic effect Effects 0.000 description 5
108010079522 solysime Proteins 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
241000233866 Fungi Species 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
235000010489 acacia gum Nutrition 0.000 description 4
239000000084 colloidal system Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
125000004356 hydroxy functional group Chemical group O* 0.000 description 4
SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 4
239000000047 product Substances 0.000 description 4
239000012927 reference suspension Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
244000215068 Acacia senegal Species 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
241000228212 Aspergillus Species 0.000 description 3
102000010911 Enzyme Precursors Human genes 0.000 description 3
108010062466 Enzyme Precursors Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229920000084 Gum arabic Polymers 0.000 description 3
239000000205 acacia gum Substances 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
244000052616 bacterial pathogen Species 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
238000005070 sampling Methods 0.000 description 3
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000008174 sterile solution Substances 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
239000000758 substrate Substances 0.000 description 3
WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
235000021314 Palmitic acid Nutrition 0.000 description 2
235000021319 Palmitoleic acid Nutrition 0.000 description 2
102000015439 Phospholipases Human genes 0.000 description 2
108010064785 Phospholipases Proteins 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
235000020661 alpha-linolenic acid Nutrition 0.000 description 2
230000003625 amylolytic effect Effects 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
125000001589 carboacyl group Chemical group 0.000 description 2
SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
230000001079 digestive effect Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
210000004051 gastric juice Anatomy 0.000 description 2
VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
229960004488 linolenic acid Drugs 0.000 description 2
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
150000004668 long chain fatty acids Chemical group 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
229910000403 monosodium phosphate Inorganic materials 0.000 description 2
235000019799 monosodium phosphate Nutrition 0.000 description 2
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
235000021313 oleic acid Nutrition 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000035040 seed growth Effects 0.000 description 2
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
150000005846 sugar alcohols Polymers 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 1
FROLUYNBHPUZQU-IIZJPUEISA-N (2R,3R,4S,5R)-2-(hydroxymethyl)-6-[3-[3-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropoxy]propoxy]oxane-3,4,5-triol Chemical compound OC[C@H]1OC(OCCCOCCCOC2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O FROLUYNBHPUZQU-IIZJPUEISA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
KDYAPQVYJXUQNY-OPHDRXFHSA-N 1,2-di-(alpha-linolenoyl)-3-[alpha-D-galactosyl-(1->6)-beta-D-galactosyl]-sn-glycerol Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](OC[C@@H](COC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KDYAPQVYJXUQNY-OPHDRXFHSA-N 0.000 description 1
WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 1
235000017060 Arachis glabrata Nutrition 0.000 description 1
235000010777 Arachis hypogaea Nutrition 0.000 description 1
235000018262 Arachis monticola Nutrition 0.000 description 1
208000035404 Autolysis Diseases 0.000 description 1
240000002791 Brassica napus Species 0.000 description 1
235000004977 Brassica sinapistrum Nutrition 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
208000000668 Chronic Pancreatitis Diseases 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
244000020551 Helianthus annuus Species 0.000 description 1
235000021353 Lignoceric acid Nutrition 0.000 description 1
CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
QUZHZFAQJATMCA-UHFFFAOYSA-N Monogalactosyldiglyceride Natural products CCC=CCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCC=CCC)COC1OC(CO)C(O)C(O)C1O QUZHZFAQJATMCA-UHFFFAOYSA-N 0.000 description 1
XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 description 1
208000016222 Pancreatic disease Diseases 0.000 description 1
208000035467 Pancreatic insufficiency Diseases 0.000 description 1
102000019280 Pancreatic lipases Human genes 0.000 description 1
108050006759 Pancreatic lipases Proteins 0.000 description 1
206010033649 Pancreatitis chronic Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
101000966369 Rhizopus oryzae Lipase Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
239000001785 acacia senegal l. willd gum Substances 0.000 description 1
GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000003243 anti-lipolytic effect Effects 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
230000002358 autolytic effect Effects 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000003858 bile acid conjugate Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
150000002016 disaccharides Chemical group 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
235000013345 egg yolk Nutrition 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
229940031098 ethanolamine Drugs 0.000 description 1
FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
208000020694 gallbladder disease Diseases 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
UOXRPRZMAROFPH-IESLQMLBSA-N lysophosphatidylinositol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC1[C@H](O)[C@@H](O)C(O)[C@@H](O)[C@H]1O UOXRPRZMAROFPH-IESLQMLBSA-N 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229930004090 phosphatidylinositide Natural products 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229950004354 phosphorylcholine Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
239000012088 reference solution Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000028043 self proteolysis Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229960001153 serine Drugs 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
238000012414 sterilization procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
238000001132 ultrasonic dispersion Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Enzymes And Modification Thereof (AREA)

SK1159-97A 1996-08-28 1997-08-22 Použitie komplexných lipidov ako stabilizujúcich prísad do farmaceutických prípravkov zmesí zažívacích enzýmov SK284639B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19634752		1996-08-28
DE19724845A DE19724845A1 (de)	1996-08-28	1997-06-12	Verwendung von komplexen Lipiden als stabilisierende Zusätze zu pharmazeutischen Zubereitungen von Verdauungsenzymgemischen

Publications (2)

Publication Number	Publication Date
SK115997A3 SK115997A3 (en)	1998-07-08
SK284639B6 true SK284639B6 (sk)	2005-08-04

Family

ID=26028823

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1159-97A SK284639B6 (sk)	1996-08-28	1997-08-22	Použitie komplexných lipidov ako stabilizujúcich prísad do farmaceutických prípravkov zmesí zažívacích enzýmov

Country Status (21)

Country	Link
US (1)	US5993806A (es)
EP (1)	EP0826375B1 (es)
JP (1)	JP4593697B2 (es)
CN (1)	CN1199694C (es)
AR (1)	AR008807A1 (es)
AT (1)	ATE284225T1 (es)
AU (1)	AU722151B2 (es)
BR (1)	BR9704554B1 (es)
CA (1)	CA2213151C (es)
CZ (1)	CZ295329B6 (es)
DE (2)	DE19724845A1 (es)
DK (1)	DK0826375T3 (es)
EE (1)	EE04179B1 (es)
ES (1)	ES2235206T3 (es)
HU (1)	HUP9701437A3 (es)
NO (1)	NO973940L (es)
NZ (1)	NZ328616A (es)
PL (1)	PL190140B1 (es)
PT (1)	PT826375E (es)
SK (1)	SK284639B6 (es)
TR (1)	TR199700872A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6074689A (en) *	1998-03-10	2000-06-13	Immucell Corporation	Colonic delivery of protein or peptide compositions
KR100367659B1 (ko) *	2000-05-08	2003-01-14	주식회사 바이넥스	선택적 안정화제의 첨가에 따른 자가분해(autolysis)를 통한 고역가 판크레아틴의 제조방법
GB0019118D0 (en) *	2000-08-03	2000-09-27	Danisco	Solid phase glycerolysis
RU2299074C2 (ru) *	2000-11-02	2007-05-20	Цилиан Аг	Применение полученных из инфузорий ферментов в качестве способствующих пищеварению лекарственных средств
US20030099626A1 (en) *	2001-11-20	2003-05-29	Health Education Corporation	Nutrient absorption enhancing compositions and methods
PT1729797E (pt) *	2004-03-22	2008-12-17	Solvay Pharm Gmbh	Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
US7153504B2 (en) *	2004-07-30	2006-12-26	Can Technologies, Inc.	Stabilized pancreas product
US7947321B2 (en) *	2005-07-20	2011-05-24	Brophy James S	Modification of particle morphology to improve product functionality
EP1913138B1 (en) *	2005-07-29	2016-08-24	Abbott Laboratories GmbH	Processes for the manufacture of pancreatin powder with low virus content
US11266607B2 (en)	2005-08-15	2022-03-08	AbbVie Pharmaceuticals GmbH	Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en)	2005-08-15	2015-12-01	Abbott Products Gmbh	Delayed release pancreatin compositions
US10072256B2 (en)	2006-05-22	2018-09-11	Abbott Products Gmbh	Process for separating and determining the viral load in a pancreatin sample
US20110183050A1 (en) *	2006-07-20	2011-07-28	Brophy James S	Modification of particle morphology to improve product functionality
US8444967B2 (en)	2010-07-09	2013-05-21	Master Supplements, Inc.	Treatment including prebiotic composition for use with probiotics
US20090130063A1 (en) *	2007-11-15	2009-05-21	Solvay Pharmaceuticals Gmbh	Process for separating and determining the viral load in a pancreatin sample
PT2391382E (pt)	2009-01-29	2014-08-22	Nordmark Arzneimittel Gmbh & Co Kg	Preparado farmacêutico contendo lipase de origem bacteriana
DE102009006594A1 (de)	2009-01-29	2010-08-05	Nordmark Arzneimittel Gmbh & Co. Kg	Pharmazeutisches Präparat
KR101968457B1 (ko)	2010-10-01	2019-04-11	앨러간 파마슈티컬스 인터내셔널 리미티드	장용 코팅된 저 강도 췌장 리파제 제제
JP2016537387A (ja)	2013-08-09	2016-12-01	アラガンファーマシューティカルズインターナショナルリミテッド	経腸投与に適した消化酵素組成物
JP2017500885A (ja) *	2013-11-05	2017-01-12	アラガンファーマシューティカルズインターナショナルリミテッド	高力価パンクレアチン医薬組成物
JP2014193909A (ja) *	2014-06-04	2014-10-09	Nordmark Arzneimittel Gmbh & Co Kg	医薬調製物
MX391630B (es) *	2014-11-05	2025-03-19	Abbott Laboratories Gmbh	Procesos para la producción de composiciones con perfil de seguridad mejorado teniendo actividad lipasa y composiciones adecuadas para medicamentos
WO2016126970A1 (en)	2015-02-04	2016-08-11	Abbvie Inc.	Pharmaceutical compositions and methods of use thereof to treat pancreatic enzyme insufficiency
DE102015114857A1 (de)	2015-09-04	2017-03-09	Nordmark Arzneimittel Gmbh & Co. Kg	Getränk, enthaltend eine pharmazeutische Zusammensetzung
DE102015114862A1 (de) *	2015-09-04	2017-03-09	Nordmark Arzneimittel Gmbh & Co. Kg	Pharmazeutische Zusammensetzung, enthaltend eine bakterielle Lipase

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3956483A (en) *	1968-10-24	1976-05-11	Wilson Pharmaceutical & Chemical Corporation	Preparing pancreatin
US3991180A (en) *	1972-03-06	1976-11-09	Rohm And Haas Company	Stabilization of internally administered pancreatic lipase
DE2512746C3 (de) *	1975-03-22	1980-04-24	Kali-Chemie Pharma Gmbh, 3000 Hannover	Verfahren zur Herstellung von keimarmem, faserfreiem Pankreatin
GB1603640A (en) *	1977-07-20	1981-11-25	Gist Brocades Nv	Enzyme particles
JPS58148814A (ja) *	1982-03-01	1983-09-05	Fujimoto Seiyaku Kk	消化酵素軟カプセル剤
JPS59169491A (ja) *	1983-03-15	1984-09-25	Duskin Franchise Co Ltd	酵素の安定化法
JPH0229950A (ja) *	1988-07-18	1990-01-31	Nec Corp	光ディスク
JP2679852B2 (ja) *	1989-11-29	1997-11-19	株式会社サム研究所	経口及び局所投与用生物活性蛋白組成物
GB9007052D0 (en) *	1990-03-29	1990-05-30	Skua Investments Ltd	Pharmaceutical formulations
RU2093996C1 (ru) *	1991-01-24	1997-10-27	Мартек Корпорейшн	Способ добавления в детскую питательную смесь докозагексановой кислоты и арахидоновой кислоты (варианты) и композиция (варианты)
DE4200002A1 (de) *	1992-01-02	1993-07-08	Rudolf V Dipl Chem Dr Noronha	Reinigungstablette fuer die zahnprothesen
AU7656894A (en) *	1993-09-15	1995-04-03	Unilever Plc	Skin care method and composition
JPH09125096A (ja) *	1995-10-30	1997-05-13	Koei Sangyo:Kk	液状天然油脂洗剤

1997
- 1997-06-12 DE DE19724845A patent/DE19724845A1/de not_active Withdrawn
- 1997-07-09 CZ CZ19972184A patent/CZ295329B6/cs not_active IP Right Cessation
- 1997-08-01 AR ARP970103511A patent/AR008807A1/es unknown
- 1997-08-18 CA CA002213151A patent/CA2213151C/en not_active Expired - Fee Related
- 1997-08-20 PT PT97114330T patent/PT826375E/pt unknown
- 1997-08-20 DK DK97114330T patent/DK0826375T3/da active
- 1997-08-20 DE DE1997512108 patent/DE59712108D1/de not_active Expired - Lifetime
- 1997-08-20 ES ES97114330T patent/ES2235206T3/es not_active Expired - Lifetime
- 1997-08-20 AT AT97114330T patent/ATE284225T1/de not_active IP Right Cessation
- 1997-08-20 EP EP97114330A patent/EP0826375B1/de not_active Expired - Lifetime
- 1997-08-22 SK SK1159-97A patent/SK284639B6/sk unknown
- 1997-08-22 US US08/916,325 patent/US5993806A/en not_active Expired - Lifetime
- 1997-08-25 HU HU9701437A patent/HUP9701437A3/hu unknown
- 1997-08-25 JP JP22800897A patent/JP4593697B2/ja not_active Expired - Lifetime
- 1997-08-27 AU AU35309/97A patent/AU722151B2/en not_active Ceased
- 1997-08-27 NO NO973940A patent/NO973940L/no not_active Application Discontinuation
- 1997-08-27 NZ NZ328616A patent/NZ328616A/xx unknown
- 1997-08-27 CN CNB971177007A patent/CN1199694C/zh not_active Expired - Fee Related
- 1997-08-27 PL PL97321825A patent/PL190140B1/pl unknown
- 1997-08-28 EE EE9700249A patent/EE04179B1/xx not_active IP Right Cessation
- 1997-08-28 BR BRPI9704554-3A patent/BR9704554B1/pt not_active IP Right Cessation
- 1997-08-28 TR TR97/00872A patent/TR199700872A2/xx unknown

Also Published As

Publication number	Publication date
PL190140B1 (pl)	2005-11-30
CZ295329B6 (cs)	2005-07-13
HK1005224A1 (en)	1998-12-31
EE04179B1 (et)	2003-12-15
NO973940L (no)	1998-03-02
DE19724845A1 (de)	1998-03-05
ES2235206T3 (es)	2005-07-01
DK0826375T3 (da)	2005-01-24
BR9704554B1 (pt)	2011-12-27
CA2213151A1 (en)	1998-02-28
EP0826375A3 (de)	2002-08-14
PL321825A1 (en)	1998-03-02
DE59712108D1 (de)	2005-01-13
EP0826375B1 (de)	2004-12-08
EE9700249A (et)	1998-04-15
JPH1077236A (ja)	1998-03-24
AR008807A1 (es)	2000-02-23
TR199700872A3 (tr)	1999-04-21
AU3530997A (en)	1998-03-05
US5993806A (en)	1999-11-30
NZ328616A (en)	1999-01-28
CN1174743A (zh)	1998-03-04
AU722151B2 (en)	2000-07-20
ATE284225T1 (de)	2004-12-15
SK115997A3 (en)	1998-07-08
CA2213151C (en)	2008-04-01
CZ218497A3 (cs)	1998-03-18
NO973940D0 (no)	1997-08-27
EP0826375A2 (de)	1998-03-04
HU9701437D0 (en)	1997-10-28
CN1199694C (zh)	2005-05-04
PT826375E (pt)	2005-02-28
TR199700872A2 (xx)	1999-04-21
HUP9701437A3 (en)	2001-03-28
HUP9701437A2 (hu)	1998-03-30
JP4593697B2 (ja)	2010-12-08
BR9704554A (pt)	1998-09-15

Publication	Publication Date	Title
SK284639B6 (sk)	2005-08-04	Použitie komplexných lipidov ako stabilizujúcich prísad do farmaceutických prípravkov zmesí zažívacích enzýmov
KR101226787B1 (ko)	2013-01-25	포스파티딜세린의 안정화된 제제
SK9292003A3 (en)	2003-12-02	Novel mixtures of microbial enzymes
Eling et al.	1971	A role for phospholipids in the binding and metabolism of drugs by hepatic microsomes. Use of the fluorescent hydrophobic probe 1-anilinonaphthalene-8-sulphonate
CN103140587B (zh)	2016-06-22	含2-酰基-溶血磷脂酰丝氨酸的组合物及其制造方法
CZ241499A3 (cs)	2000-01-12	Peptid a farmaceutický prostředek
Satoh et al.	1973	Comparative studies on the inhibition of liver amidases, aminopeptidase and serum cholinesterases by EPN
HK1005224B (en)	2005-08-05	Use of complex lipide as stabilizing additives in pharmaceutical formulation of digestive enzyme mixture
US6420156B2 (en)	2002-07-16	Purified proteolytic enzyme and method of purification
JP5017622B2 (ja)	2012-09-05	血液凝固反応抑制剤
US20120129808A1 (en)	2012-05-24	Blood coagulation reaction inhibitor
JP2007091625A (ja)	2007-04-12	血液凝固反応促進剤
JP2007106679A (ja)	2007-04-26	血液凝固反応促進剤
JP2007145757A (ja)	2007-06-14	血液凝固反応抑制剤
JPH03127731A (ja)	1991-05-30	ビタミンｅの可溶化方法およびビタミンｅ製剤
JPH04131082A (ja)	1992-05-01	非水系高活性酵素の製造方法
HK1092703B (en)	2013-05-10	Stabilized formulations of phosphatidylserine